An “immuno-gene” therapy that turns a virus into a cancer-fighting agent has received a fast-track designation from the U.S. Food and Drug Administration (FDA). The…
Glioma
Telix Pharmaceuticals has submitted an application to European regulators seeking approval for TLX101-Px, the company’s experimental imaging agent designed to help guide treatment decisions…
Nuvation Bio expanded a trial testing its experimental therapy, safusidenib, in people with certain forms of glioma that carry an IDH1 mutation, transitioning…
A team of scientists at the University of Cincinnati Cancer Center is embarking on a series of tests to evaluate an experimental immune-modulating treatment strategy…
The majority of patients with recurrent glioblastoma remain alive following treatment with an experimental immune-modulating combination, according to a clinical trial update from Immunitybio.
Curasight‘s experimental cancer therapy, uTREAT, has successfully reached its target in the brain of the first patient dosed in a Phase 1 clinical trial.
Treatment with DeltEx DRI, a cell therapy developed by In8bio, is prolonging survival outcomes among people with newly diagnosed glioblastoma in a clinical…
TTX-MC138, an RNA-based therapy from Transcode Therapeutics that’s in early clinical development, induced tumor cell death and prolonged survival in a mouse model of…
The first participant has been dosed in an early clinical trial testing the experimental radiation therapy Alpha DaRT in people with hard-to-treat glioma. The…
Treatment with the experimental medication eflornithine in combination with the approved chemotherapy Gleostine (lomustine) may help improve survival in people with aggressive astrocytoma carrying IDH…
